Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases
Open accessThe DOI matches its Crossref record; 793 of the 793 references it cites were found in a registry or an index; 233 of the 632 sources its claims cite were checked for support.
Abstract
The human gastrointestinal tract is populated with a diverse microbial community. The vast genetic and metabolic potential of the gut microbiome underpins its ubiquity in nearly every aspect of human biology, including health maintenance, development, aging, and disease. The advent of new sequencing technologies and culture-independent methods has allowed researchers to move beyond correlative studies toward mechanistic explorations to shed light on microbiome–host interactions. Evidence has unveiled the bidirectional communication between the gut microbiome and the central nervous system, referred to as the “microbiota–gut–brain axis”. The microbiota–gut–brain axis represents an important regulator of glial functions, making it an actionable target to ameliorate the development and progression of neurodegenerative diseases. In this review, we discuss the mechanisms of the microbiota–gut–brain axis in neurodegenerative diseases. As the gut microbiome provides essential cues to microglia, astrocytes, and oligodendrocytes, we examine the communications between gut microbiota and these glial cells during healthy states and neurodegenerative diseases. Subsequently, we discuss the mechanisms of the microbiota–gut–brain axis in neurodegenerative diseases using a metabolite-centric approach, while also examining the role of gut microbiota-related neurotransmitters and gut hormones. Next, we examine the potential of targeting the intestinal barrier, blood–brain barrier, meninges, and peripheral immune system to counteract glial dysfunction in neurodegeneration. Finally, we conclude by assessing the pre-clinical and clinical evidence of probiotics, prebiotics, and fecal microbiota transplantation in neurodegenerative diseases. A thorough comprehension of the microbiota–gut–brain axis will foster the development of effective therapeutic interventions for the management of neurodegenerative diseases.
Overview
CoChat Summary
TL;DR
This review synthesizes mechanistic and therapeutic evidence on the microbiota–gut–brain axis in neurodegenerative diseases, emphasizing bidirectional communication between gut microbiota and glial cells (microglia, astrocytes, oligodendrocytes). It argues that gut-derived metabolites, neurotransmitters, and hormones modulate glial function via the intestinal barrier, blood–brain barrier, meninges, and peripheral immune system, and assesses probiotics, prebiotics, and FMT as therapeutic strategies.
Key findings
- The gut microbiome regulates microglial maturation and function largely via short-chain fatty acids (SCFAs); germ-free and antibiotic-treated mice show impaired microglial immune responses that are partially restored by recolonization or SCFA supplementation. Among neuronal and glial cells, microglia are described as the most vulnerable to gut microbiome alterations.
- In AD models, germ-free or antibiotic-treated APP/PS1 and 5xFAD mice show reduced Aβ pathology and microglial activation, and FMT from AD patients or conventionally raised mice restores pathology; effects are sex-dependent (e.g., absent in female APP/PS1-21 mice). In PD, germ-free/antibiotic-treated α-synuclein-overexpressing mice show less pathology, and FMT from PD patients restores motor dysfunction.
- Metabolite-centric evidence is context-dependent: SCFAs are largely neuroprotective in PD but show conflicting (both protective and detrimental) effects in AD; TMAO promotes microglial/astrocytic activation and Aβ/tau pathology; secondary bile acids UDCA/TUDCA are neuroprotective; indole derivatives act via AHR; BCAAs promote anti-inflammatory microglial phenotypes; nicotinamide (NAM) is reduced in ALS serum and CSF.
- Clinical translation is mixed: probiotics/prebiotics improve constipation-related parameters and some cognitive/motor scores in PD and MCI trials, but several AD trials show no significant cognitive benefit; the paper notes a 95% positive-result rate in human microbiota-associated rodent studies warrants caution.
Methods
- Narrative review (not a primary study) covering mechanisms of the microbiota–gut–brain axis in AD, PD, ALS, HD, and FTD, with emphasis on glial interactions.
- Synthesizes preclinical (germ-free, antibiotic-treated, FMT, transgenic mouse models) and clinical evidence, including tables of in vivo probiotic/prebiotic/FMT studies and completed/ongoing clinical trials (Tables 1–5).
- Uses a metabolite-centric framing (SCFAs, bile acids, TMAO, tryptophan/indoles, PUFAs, BCAAs, NAM) plus gut microbiota-related neurotransmitters (serotonin, GABA, dopamine, acetylcholine, glutamate) and gut hormones (ghrelin, leptin, GLP-1).
Limitations
- Stated: establishing causality between altered gut microbiome and disease is difficult (causative vs. consequential vs. bystander); animal models do not fully recapitulate human microbiome/pathobiology; the 95% positive-result rate in human microbiota-associated rodents demands caution against overstating causal claims.
- Stated: many SCFA studies reporting detrimental effects used germ-free mice, which are physiologically abnormal, limiting extrapolation to humans; heterogeneity across AD mouse models complicates predicting SCFA implications.
- Stated: clinical trials often lack gut microbiome profiling, limiting pre/post comparison; few trials exist in ALS, FTD, and HD; FMT is limited by variable engraftment, limited scalability, lack of standardized protocols, and pathogen-transmission risk. Evident from the text: much of the mechanistic evidence is preclinical, and several findings (e.g., TMAO in PD, astrocyte studies relying on GFAP densitometry) are explicitly described as conflicting or methodologically limited.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
111 Valid · 10 Not valid · 252 Not checked · 37 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Ultimately, the activation of microglia by these protein aggregates creates a feed-forward vicious cycle that aggravates neurodegeneration as activated microglia contribute to the propagation of tau, Aβ, α-synuclein, and TDP-43 into unaffected brain regions.159–164”
§ Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases > Roles of microglia in neurodegenerative diseases > Microglia-mediated neuroinflammation
What the sources say
- Partly supportedcites [159] Brelstaff JH Microglia become hypofunctional and release metalloproteases and tau seeds when phagocytosing live neurons with P301S tau aggregates Sci. Adv. 2021 7 eabg4980 10.1126/sciadv.abg4980 34669475 PMC8528424 sourceExperimental — accuracy not yet measured
The Discussion (Fig. 7; page not available in our copy) proposes a self-amplifying cycle in which microglia that phagocytose tau-bearing neurons release tau seeds that induce further aggregation. The Introduction describes microglia as possible vectors of tau spread in the local environment. The paper does not establish microglial propagation of Aβ, α-synuclein, or TDP-43, or demonstrate spread into unaffected brain regions. (LLM, conf=0.88)
- Supportedcites [160] d’Errico P Microglia contribute to the propagation of Aβ into unaffected brain tissue Nat. Neurosci. 2022 25 20 25 10.1038/s41593-021-00951-0 34811521 PMC8737330 source
The Main section says microglia become reactive around Aβ plaques and carry Aβ into previously unaffected brain tissue. The Abstract likewise reports that microglia carry Aβ pathology into unaffected tissue. In this multi-citation sentence, this paper supports the Aβ-propagation component; it is not evidence for propagation of the other named proteins. (LLM, conf=0.90)
- Partly supportedcites [161] George S Microglia affect α-synuclein cell-to-cell transfer in a mouse model of Parkinson’s disease Mol. Neurodegener. 2019 14 34 10.1186/s13024-019-0335-3 31419995 PMC6697982 sourceExperimental — accuracy not yet measured
The Background describes a proposed vicious cycle in which aggregated α-synuclein activates microglia and inflammatory mediators promote further α-synuclein aggregation. The Discussion reports increased α-synuclein transfer to grafted neurons after LPS-induced microglial activation. The paper does not establish that activated microglia propagate tau, Aβ, or TDP-43 into unaffected brain regions; its transfer findings concern α-synuclein in a mouse transplantation model. (LLM, conf=0.88)
- Partly supportedcites [162] Pascoal TA Microglial activation and tau propagate jointly across Braak stages Nat. Med. 2021 27 1592 1599 10.1038/s41591-021-01456-w 34446931 sourceExperimental — accuracy not yet measured
The Discussion reports that microglial activation and tau spread together across brain regions, with Aβ potentiating the effect of microglial activation on tau spread. It does not establish that activated microglia propagate Aβ, α-synuclein, or TDP-43, or demonstrate the claimed feed-forward vicious cycle. The paper also frames its human findings as associations rather than proof of that causal cycle. (LLM, conf=0.88)
- Supportedcites [163] Guo M Microglial exosomes facilitate α-synuclein transmission in Parkinson’s disease Brain 2020 143 1476 1497 10.1093/brain/awaa090 32355963 PMC7241957 source
For this multi-cited sentence, the paper supports the α-synuclein portion. The Introduction reports that α-synuclein activates microglia and that their inflammatory cytokines enhance exosome-induced aggregation and spreading; the Results also report that microglial inflammation accelerated α-synuclein transmission. This paper is not being treated as evidence for every protein named in the sentence. (LLM, conf=0.88)
- Disputedcites [164] Svahn AJ Nucleo-cytoplasmic transport of TDP-43 studied in real time: impaired microglia function leads to axonal spreading of TDP-43 in degenerating motor neurons Acta Neuropathol. 2018 136 445 459 10.1007/s00401-018-1875-2 29943193 PMC6096729 sourceExperimental — accuracy not yet measured
The Discussion says normal microglia prevent TDP-43 spreading by engulfing injured motor neurons; axonal and extracellular spreading occurred when functional microglia were depleted. That is contrary to the claim that activated microglia propagate TDP-43. The cited paper does not establish the claim about tau, Aβ, or α-synuclein. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Similarly, the gut microbiota is required for microglial activation in 5xFAD mice.203–205”
§ Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases > Microbiota–gut–brain axis in neurodegenerative diseases > Interaction between gut microbiota and microglia
What the sources say
- Supportedcites [203] Wang X Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer’s disease progression Cell Res. 2019 29 787 803 10.1038/s41422-019-0216-x 31488882 PMC6796854 source
The Results section headed 'Gut microbiota is required for immune cell infiltration and microglial activation in the brain' states that gut-microbiota ablation by an antibiotic cocktail in 5XFAD transgenic (Tg) mice produced a marked reduction in microbial abundance along with a reduction in both infiltrating pro-inflammatory Th1 cells and M1 microglia in the brain. Fig. 2's legend ('The gut microbiota is required for immune cell infiltration and microglial activation', five-month oral gavage of ABX in 7-month-old 5XFAD Tg mice) and the Discussion ('dysbiosis of the gut microbiota is required for the infiltration of various peripheral immune cells... gut dysbiosis promotes Th1 cell infiltration... and in turn triggers the microglia differentiation towards a pro-inflammatory state') restate the same point, matching the claim's population (5xFAD mice) and conclusion. (LLM, conf=0.92)
- Partly supportedcites [204] Chen C Gut dysbiosis contributes to amyloid pathology, associated with C/EBPβ/AEP signaling activation in Alzheimer’s disease mouse model Sci. Adv. 2020 6 eaba0466 10.1126/sciadv.aba0466 32832679 PMC7439296 sourceExperimental — accuracy not yet measured
Our copy does contain a relevant own-data result: in the Results section 'Antibiotic treatment represses C/EBPβ/AEP signaling in 5xFAD mice, alleviating AD pathologies', chronic ABX depletion of the gut microbiota lowered the microglial marker signal ('Positive signals from Iba-1, a microglia/macrophage-specific calcium-binding protein as microglia marker, were reduced upon ABX treatment (fig. S3E)'), so the direction of the claim (microbiota loss dampens microgliosis in 5xFAD) is present. However, the paper never states that the microbiota is 'required' for microglial activation, and it reports only a marker-density change, not activation phenotyping; the causal microbiota-to-microglia conclusion it invokes is credited to other works in the Discussion (Minter et al., ref 10, for reduced Aβ deposition and associated gliosis; Dodiya et al., ref 41, for fecal transplant partially restoring Aβ pathology and microglial morphology in APP/PS1-21, not 5xFAD). The remaining prompt passages characterize dysbiosis in 5xFAD stool (Fig. 1, fig. S1) and say nothing about microglia. (LLM, conf=0.72)
- Disputedcites [205] Mezö C Different effects of constitutive and induced microbiota modulation on microglia in a mouse model of Alzheimer’s disease Acta Neuropathol. Commun. 2020 8 119 10.1186/s40478-020-00988-5 32727612 PMC7389451 sourceExperimental — accuracy not yet measured
Our copy never states that microbiota is required for microglial activation in 5xFAD mice; it frames the relationship as modulation, and its data run the other way. In Results 'Permanent absence of microbes alters microglial gene profile in GF 5xFAD mice' the authors report UPREGULATED AD-associated activation markers (Apoe, Trem2, Axl, Cst7, Itgax/CD11c, Cd9, Clec7a, with reduced P2ry12) in microglia from germ-free 5xFAD mice, concluding the AD-linked activation signature 'can be modulated by host microbiota'. The Discussion likewise describes 'a certain microbiota-dependent influence on this microglial activation state' and increased microglial density, plaque association and Aβ uptake under GF conditions, while only neuroinflammation/chemokine signaling pathways were diminished — i.e., activation occurs in the absence of microbiota, not as a microbiota-required phenomenon. (LLM, conf=0.75)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Although studies in AD patients have yielded slightly heterogeneous results in BA composition, they have reported a consistent pattern of reduced levels of primary BAs and elevated levels of secondary BAs.”
§ Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases > Gut microbiota-derived metabolites in neurodegenerative diseases > Bile acids regulate neuroinflammation and neurodegeneration
What the sources say
- Partly supportedcites [355] Baloni P Metabolic network analysis reveals altered bile acid synthesis and metabolism in Alzheimer’s disease Cell Rep. Med. 2020 1 100138 10.1016/j.xcrm.2020.100138 33294859 PMC7691449 sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) says increased secondary bile acid levels and increased ratios to primary bile acids have been linked to AD. The Results (page unavailable) report higher ratios to cholic acid for several secondary bile acids in AD brain samples, but also for primary bile acids including CDCA and TCA. These ratios do not establish a consistent reduction in primary bile acid levels. (LLM, conf=0.86)
- Partly supportedcites [356] MahmoudianDehkordi S Altered bile acid profile associates with cognitive impairment in Alzheimer’s disease—an emerging role for gut microbiome Alzheimers Dement. 2019 15 76 92 10.1016/j.jalz.2018.07.217 30337151 PMC6487485 sourceExperimental — accuracy not yet measured
The Results section reports lower levels of one primary bile acid (CA) and higher levels of DCA and several secondary bile acids in AD patients. The Discussion notes that an earlier study did not find a significant decrease in CA, so the source does not establish a consistent reduction in primary bile acids across studies. (LLM, conf=0.86)
- Partly supportedcites [357] Nho K Altered bile acid profile in mild cognitive impairment and Alzheimer’s disease: relationship to neuroimaging and CSF biomarkers Alzheimers Dement. 2019 15 232 244 10.1016/j.jalz.2018.08.012 30337152 PMC6454538 sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) reports that increased secondary bile acids and higher secondary-to-primary bile acid ratios were associated with AD and poor cognition. It does not report reduced primary bile acid levels in AD patients, so it does not establish the claimed consistent pattern across studies. (LLM, conf=0.84)
- Disputedcites [358] Varma VR Bile acid synthesis, modulation, and dementia: a metabolomic, transcriptomic, and pharmacoepidemiologic study PLoS Med. 2021 18 e1003615 10.1371/journal.pmed.1003615 34043628 PMC8158920 sourceExperimental — accuracy not yet measured
The Results (Step 3; page unavailable) report marginally higher, not lower, concentrations of the primary bile acids CA and CDCA in AD brain samples than in controls, although the difference was nonsignificant. The Discussion reports a previous study finding lower plasma CA in AD and a higher secondary-to-primary bile-acid ratio associated with cognitive impairment, but neither establishes the claimed consistent pattern of reduced primary and elevated secondary bile-acid levels. (LLM, conf=0.86)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Moreover, studies on animal models have provided compelling evidence that the altered gut microbiome drives neurodegenerative disease pathogenesis, primarily through the modulation of microglial functions and activation.54–57”
§ Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases > Introduction
What the sources say
- Partly supportedcites [54] Dodiya HB Gut microbiota-driven brain Aβ amyloidosis in mice requires microglia J. Exp. Med. 2022 219 e20200895 10.1084/jem.20200895 34854884 PMC8647415 sourceExperimental — accuracy not yet measured
Our copy supports the core of the attribution: the Abstract and the Results section 'Microglia play an essential role in mediating short-term ABX-perturbed microbiome's effect on Aβ amyloidosis' establish causality between an antibiotic-perturbed gut microbiota, microglia, Aβ and neurodegeneration, and the Introduction states that microglial depletion with PLX5622 'argues for an essential role of microglia in mediating microbiome-driven brain amyloidosis'. However, that causal demonstration is confined to Aβ amyloidosis in male APPPS1-21 mice (the Introduction repeatedly notes the effects are 'specific to male animals'), whereas the citing sentence extends it to neurodegenerative disease pathogenesis in general; for the other disorders it lists (PD, MS, brain injury, stroke) the source only says a dysfunctional microbiota–brain axis 'might play an important role' and that the gut microbiome 'potentially' affects neurodegeneration. The 'primarily through modulation of microglial functions and activation' mechanism is also not settled by the source, which states in the Discussion that 'the mechanism(s) underlying this fascinating result remains to be established' while offering scenarios. (LLM, conf=0.75)
- Partly supportedcites [55] Sampson TR Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson’s disease Cell 2016 167 1469 1480.e1412 10.1016/j.cell.2016.11.018 27912057 PMC5718049 sourceExperimental — accuracy not yet measured
Sampson et al. 2016 does supply animal-model evidence that gut microbiota drive disease in a Parkinson's (α-synuclein overexpressing) mouse model via microglia: the SUMMARY (p. 3) reports 'gut microbiota are required for motor deficits, microglia activation, and αSyn pathology,' and the DISCUSSION (p. 10) links this to microbiota-dependent microglia maturation/activation by SCFAs. However, the source hedges the mechanism as 'one potential pathway' within mechanisms that are 'likely complex,' and the DISCUSSION (p. 11) explicitly posits other, undiscovered disease-modifying processes (autophagy, proteasome function) — so the claim's 'primarily through the modulation of microglial functions' overstates it. The generalization from a single synucleinopathy model to 'neurodegenerative disease pathogenesis' broadly is also beyond the paper, which only speculates that other amyloid disorders such as Alzheimer's and Huntington's 'may be impacted' (p. 11) and confines its conclusions to PD/synucleinopathies (pp. 10, 12). (LLM, conf=0.78)
- Partly supportedcites [56] Seo D-o ApoE isoform- and microbiota-dependent progression of neurodegeneration in a mouse model of tauopathy Science 2023 379 eadd1236 10.1126/science.add1236 36634180 PMC9901565 sourceExperimental — accuracy not yet measured
Our copy of Seo et al. (Science 2023) is a mouse tauopathy study and does support the core of the claim: germ-free rearing and antibiotic-induced microbiota perturbation reduced gliosis, tau pathology and neurodegeneration, with the GF rescue reversed by fecoral colonization from conventionally-raised donors, and the paper concludes 'GF conditions affect microglia and astrocyte reactivity or activation associated with tau-mediated neurodegeneration' (sections 'TE4 Germ-free mice exhibit reduced reactive gliosis', 'Antibiotic-treatment alters astrocyte and microglial gene expression and morphological responses'). However, the claim's 'primarily through the modulation of microglial functions and activation' narrows the source wrongly: the paper implicates astrocytes at least as strongly (disease-associated astrocyte phenotypes, GFAP/Iba1/CD68 staining, snRNA-seq astrocyte and microglial subcluster shifts, SCFA effects) alongside peripheral immune and metabolic signalling. The effect is also bounded in ways the claim drops — it was sex- and ApoE-isoform-dependent (ABX protected male TE3 but largely not TE4/APOE4 mice), and the authors frame the mechanism as hypothesis ('we hypothesize that the gut microbiota regulates the brain's innate immune response', Conclusion) rather than settled 'compelling' causation across neurodegenerative disease generally. (LLM, conf=0.72)
- Partly supportedcites [57] Burberry A C9orf72 suppresses systemic and neural inflammation induced by gut bacteria Nature 2020 582 89 94 10.1038/s41586-020-2288-7 32483373 PMC7416879 sourceExperimental — accuracy not yet measured
Our copy is an animal-model study that does support the core link: in the C9orf72Harvard loss-of-function mice, suppressing gut microflora with antibiotics or transplanting flora from a protective environment attenuated systemic and neural inflammation (Abstract; 'Antibiotics prevent inflammation'), and microglial pro-inflammatory markers Dectin1 and Ccr9 were significantly reduced by antibiotic treatment ('Environment governs neuroinflammation'). But the claim's 'primarily through the modulation of microglial functions and activation' is not what this paper concludes: its summary passage attributes the effect to both peripheral immune-cell infiltration of the spinal cord and microglial activation, and it explicitly found that microglial lysosomal markers (Lamp1, Cathepsin B) were NOT decreased by lifelong microbiota suppression, i.e. regulated 'independently from microbial signals'. The paper also hedges ('signals derived from gut bacteria promote inflammation and autoimmunity when C9orf72 function is diminished'; 'the microbiome may be an important governor') and confines this to C9orf72-related ALS/FTD in mice, noting the general microglia-maturation point belongs to other works it cites (ref 31, and refs 33-34 for Alzheimer's/Parkinson's models, Discussion). So the specific mechanism emphasis and the broad 'neurodegenerative disease pathogenesis' scope overstate this source. (LLM, conf=0.78)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Evidence has unveiled the bidirectional communication between the gut microbiome and the central nervous system, referred to as the “microbiota–gut–brain axis”.”
- Also stated in: § Introduction · boosted
“Accumulating evidence has unveiled the bidirectional communication between the gut microbiome and central nervous system (CNS), referred to as the “microbiota–gut–brain axis”.30,31”
§ Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases > Abstract
What the sources say
- Supportedcites [30] Ahmed H Microbiota-derived metabolites as drivers of gut-brain communication Gut Microbes 2022 14 2102878 10.1080/19490976.2022.2102878 35903003 PMC9341364 source
The Introduction describes a bidirectional communication network between the central nervous system and intestine and says that gut microbiota signals the brain through it. The Enteric nervous system section also describes a loop of gut–brain–gut signaling. Together, these passages support the citing sentence’s description of the microbiota–gut–brain axis. (LLM, conf=0.92)
- Not checked yetcites [31] Morais LH Schreiber HL Mazmanian SK The gut microbiota–brain axis in behaviour and brain disorders Nat. Rev. Microbiol. 2021 19 241 255 10.1038/s41579-020-00460-0 33093662 source
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Introduction · boosted
254 more claims · 79 with their cited sources checked
Create a free account to see all 410 claims and to verify the 399 references still open.
- It may state two separate claims as one. 140
- Probably not a substantial claim. 18
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Recent research has increasingly underscored the pivotal role of the gut microbiota in modulating the GBA.”
From The hidden genetic and microbial networks connecting neuropsychiatric and digestive disorders (2025) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases > Microbiome-based therapeutics > Clinical applications of microbiome-based therapeutics
“| Probiotic sachets containing:- Bifidobacterium breve A1 (MCC1274) | AD | AD patients N = 60 (Control)N = 55 (Intervention)”
§ Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases > References
“778. Asaoka D Effect of probiotic Bifidobacterium breve in improving cognitive function and preventing brain atrophy in older patients with suspected mild cognitive impairment: results of a 24-week randomized, double-blind, placebo-controlled trial”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases > Microbiome-based therapeutics > Probiotics and prebiotics
“| Probiotic suspension Symprove™ | DSP-4 and 6-OHDA-induced PD mice | Daily treatment for 24 days”
§ Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases > References
“760. Sancandi M Effects of a probiotic suspension Symprove™ on a rat early-stage Parkinson’s disease model”
Citations
Cites
1 retracted
Items 401–600 of 793
Microglial Piezo1 senses Aβ fibril stiffness to restrict Alzheimer’s disease
Hu, J., Chen, Q., Zhu, H., Hou, L., Liu, W., Yang, Q., Shen, H., Chai, G., Zhang, B., Chen, S., et al. (2023) · Neuron · doi:10.1016/j.neuron.2022.10.021 · Cited by 193
Nunes, A. F., Amaral, J. D., Lo, A. C., Fonseca, M. B., Viana, R. J. S., Callaerts-Vegh, Z., D’Hooge, R., & Rodrigues, C. M. P. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8256-y · Cited by 192
Park, J.-S., Kam, T.-I., Lee, S., Park, H., Oh, Y., Kwon, S.-H., Song, J.-J., Kim, D., Kim, H., Jhaldiyal, A., et al. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01180-z · Cited by 192
d-glutamate and Gut Microbiota in Alzheimer’s Disease
Chang, C.-H., Lin, C.-H., & Lane, H.-Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082676 · Cited by 191
Bido, S., Muggeo, S., Massimino, L., Marzi, M. J., Giannelli, S. G., Melacini, E., Nannoni, M., Gambarè, D., Bellini, E., Ordazzo, G., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26519-x · Cited by 190
Fetal meconium does not have a detectable microbiota before birth
Kennedy, K. M., Gerlach, M. J., Adam, T., Heimesaat, M. M., Rossi, L., Surette, M. G., Sloboda, D. M., & Braun, T. (2021) · Nature Microbiology · doi:10.1038/s41564-021-00904-0 · Cited by 188
Gastrointestinal involvement in Parkinson’s disease: pathophysiology, diagnosis, and management
Warnecke, T., Schäfer, K.-H., Claus, I., Del Tredici, K., & Jost, W. H. (2022) · npj Parkinson's Disease · doi:10.1038/s41531-022-00295-x · Cited by 188
Worby, C. J., Schreiber, H. L., Straub, T. J., van Dijk, L. R., Bronson, R. A., Olson, B. S., Pinkner, J. S., Obernuefemann, C. L. P., Muñoz, V. L., Paharik, A. E., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01107-x · Cited by 188
Huang, B., Chau, S. W. H., Liu, Y., Chan, J. W. Y., Wang, J., Ma, S. L., Zhang, J., Chan, P. K. S., Yeoh, Y. K., Chen, Z., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38248-4 · Cited by 187
Microglial immune checkpoint mechanisms
Deczkowska, A., Amit, I., & Schwartz, M. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0145-x · Cited by 185
Palmnäs-Bédard, M. S., Costabile, G., Vetrani, C., Åberg, S., Hjalmarsson, Y., Dicksved, J., Riccardi, G., & Landberg, R. (2022) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqac217 · Cited by 185
Adesso, S., Magnus, T., Cuzzocrea, S., Campolo, M., Rissiek, B., Paciello, O., Autore, G., Pinto, A., & Marzocco, S. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00370 · Cited by 184
Microglia regulation of central nervous system myelin health and regeneration
Kent, S. A., & Miron, V. E. (2024) · Nature Reviews Immunology · doi:10.1038/s41577-023-00907-4 · Cited by 183
Gut-innervating nociceptors regulate the intestinal microbiota to promote tissue protection
Zhang, W., Lyu, M., Bessman, N. J., Xie, Z., Arifuzzaman, M., Yano, H., Parkhurst, C. N., Chu, C., Zhou, L., Putzel, G. G., et al. (2022) · Cell · doi:10.1016/j.cell.2022.09.008 · Cited by 181
Paganoni, S., Hendrix, S., Dickson, S. P., Knowlton, N., Macklin, E. A., Berry, J. D., Elliott, M. A., Maiser, S., Karam, C., Caress, J. B., et al. (2021) · Muscle & Nerve · doi:10.1002/mus.27091 · Cited by 180
The synapse as a treatment avenue for Alzheimer’s Disease
Peng, L., Bestard‐Lorigados, I., & Song, W. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01565-z · Cited by 180
Evaluation of fecal microbiota transplantation in Parkinson's disease patients with constipation
Kuai, X.-Y., Yao, X.-H., Xu, L.-J., Zhou, Y.-Q., Zhang, L.-P., Liu, Y., Pei, S.-F., & Zhou, C.-L. (2021) · Microbial Cell Factories · doi:10.1186/s12934-021-01589-0 · Cited by 179
Seethaler, B., Nguyen, N. K., Basrai, M., Kiechle, M., Walter, J., Delzenne, N. M., & Bischoff, S. C. (2022) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqac175 · Cited by 179
Dopamine and glutamate regulate striatal acetylcholine in decision-making
Chantranupong, L., Beron, C. C., Zimmer, J. A., Wen, M. J., Wang, W., & Sabatini, B. L. (2023) · Nature · doi:10.1038/s41586-023-06492-9 · Cited by 178
APOE genotype regulates pathology and disease progression in synucleinopathy
Davis, A. A., Inman, C. E., Wargel, Z. M., Dube, U., Freeberg, B. M., Galluppi, A., Haines, J. N., Dhavale, D. D., Miller, R., Choudhury, F. A., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay3069 · Cited by 177
The Gut Microbial Bile Acid Modulation and Its Relevance to Digestive Health and Diseases
Fogelson, K. A., Dorrestein, P. C., Zarrinpar, A., & Knight, R. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.02.022 · Cited by 177
Astrocyte-oligodendrocyte interaction regulates central nervous system regeneration
Molina-Gonzalez, I., Holloway, R. K., Jiwaji, Z., Dando, O., Kent, S. A., Emelianova, K., Lloyd, A. F., Forbes, L. H., Mahmood, A., Skripuletz, T., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39046-8 · Cited by 176
Qin, Y., Qiu, J., Wang, P., Liu, J., Zhao, Y., Jiang, F., & Lou, H. (2021) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.10.010 · Cited by 175
The gut microbiota contributes to the pathogenesis of anorexia nervosa in humans and mice
Fan, Y., Støving, R. K., Ibraim, S. B., Hyötyläinen, T., Thirion, F., Arora, T., Lyu, L., Stankevič, E., Hansen, T. H., Déchelotte, P., et al. (2023) · Nature Microbiology · doi:10.1038/s41564-023-01355-5 · Cited by 175
Ibrahim, A., Ali, R. A. R., Manaf, M. R. A., Ahmad, N., Tajurruddin, F. W., Qin, W. Z., Desa, S. H. M., & Ibrahim, N. M. (2020) · PLOS ONE · doi:10.1371/journal.pone.0244680 · Cited by 174
Longevity of centenarians is reflected by the gut microbiome with youth-associated signatures
Pang, S., Chen, X., Lu, Z., Meng, L., Huang, Y., Yu, X., Huang, L., Ye, P., Chen, X., Liang, J., et al. (2023) · Nature Aging · doi:10.1038/s43587-023-00389-y · Cited by 173
Da Mesquita, S., Herz, J., Wall, M., Dykstra, T., de Lima, K. A., Norris, G. T., Dabhi, N., Kennedy, T., Baker, W., & Kipnis, J. (2021) · Science Advances · doi:10.1126/sciadv.abe4601 · Cited by 172
Intrinsic dopamine and acetylcholine dynamics in the striatum of mice
Krok, A. C., Maltese, M., Mistry, P. N., Miao, X., Li, Y., & Tritsch, N. X. (2023) · Nature · doi:10.1038/s41586-023-05995-9 · Cited by 172
Xu, Y., Propson, N. E., Du, S., Xiong, W., & Zheng, H. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2023418118 · Cited by 171
Oral administration of Proteus mirabilis damages dopaminergic neurons and motor functions in mice
Choi, J. G., Kim, N., Ju, I. G., Eo, H., Lim, S.-M., Jang, S.-E., Kim, D.-H., & Oh, M. S. (2018) · Scientific Reports · doi:10.1038/s41598-018-19646-x · Cited by 170
Wei, B.-Z., Li, L., Dong, C.-W., Tan, C.-C., & Xu, W. (2023) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2023.04.001 · Cited by 169
Liu, C.-C., Zhao, J., Fu, Y., Inoue, Y., Ren, Y., Chen, Y., Doss, S. V., Shue, F., Jeevaratnam, S., Bastea, L., et al. (2022) · Nature Neuroscience · doi:10.1038/s41593-022-01127-0 · Cited by 168
Toubal, A., Kiaf, B., Beaudoin, L., Cagninacci, L., Rhimi, M., Fruchet, B., da Silva, J., Corbett, A. J., Simoni, Y., Lantz, O., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17307-0 · Cited by 165
Lee, H.-J., Lee, K.-E., Kim, J.-K., & Kim, D.-H. (2019) · Scientific Reports · doi:10.1038/s41598-019-48342-7 · Cited by 164
Fernando, W. M. A. D. B., Martins, I. J., Morici, M., Bharadwaj, P., Rainey-Smith, S. R., Lim, W. L. F., & Martins, R. N. (2020) · Journal of Alzheimer's Disease · doi:10.3233/jad-190120 · Cited by 164
Human-Derived Bifidobacterium dentium Modulates the Mammalian Serotonergic System and Gut–Brain Axis
Engevik, M. A., Luck, B., Visuthranukul, C., Ihekweazu, F. D., Engevik, A. C., Shi, Z., Danhof, H. A., Chang-Graham, A. L., Hall, A., Endres, B. T., et al. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2020.08.002 · Cited by 164
Single-nucleus multiregion transcriptomic analysis of brain vasculature in Alzheimer’s disease
Sun, N., Akay, L. A., Murdock, M. H., Park, Y., Galiana-Melendez, F., Bubnys, A., Galani, K., Mathys, H., Jiang, X., Ng, A. P., et al. (2023) · Nature Neuroscience · doi:10.1038/s41593-023-01334-3 · Cited by 164
Weng, Z., Signore, A. P., Gao, Y., Wang, S., Zhang, F., Hastings, T., Yin, X.-M., & Chen, J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m705426200 · Cited by 163
DuPont, H. L., Suescun, J., Jiang, Z.-D., Brown, E. L., Essigmann, H. T., Alexander, A. S., DuPont, A. W., Iqbal, T., Utay, N. S., Newmark, M., et al. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1104759 · Cited by 162
Liao, J.-F., Cheng, Y.-F., You, S.-T., Kuo, W.-C., Huang, C.-W., Chiou, J.-J., Hsu, C.-C., Hsieh-Li, H.-M., Wang, S., & Tsai, Y.-C. (2020) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.07.036 · Cited by 159
Haure-Mirande, J.-V., Audrain, M., Ehrlich, M. E., & Gandy, S. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00552-w · Cited by 159
Blood–brain barrier link to human cognitive impairment and Alzheimer’s disease
Barisano, G., Montagne, A., Kisler, K., Schneider, J. A., Wardlaw, J. M., & Zlokovic, B. V. (2022) · Nature Cardiovascular Research · doi:10.1038/s44161-021-00014-4 · Cited by 157
Castro-Caldas, M., Carvalho, A. N., Rodrigues, E., Henderson, C. J., Wolf, C. R., Rodrigues, C. M. P., & Gama, M. J. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8295-4 · Cited by 156
Velazquez, R., Ferreira, E., Knowles, S., Fux, C., Rodin, A., Winslow, W., & Oddo, S. (2019) · Aging Cell · doi:10.1111/acel.13037 · Cited by 156
APOE4 exacerbates α-synuclein pathology and related toxicity independent of amyloid
Zhao, N., Attrebi, O. N., Ren, Y., Qiao, W., Sonustun, B., Martens, Y. A., Meneses, A. D., Li, F., Shue, F., Zheng, J., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay1809 · Cited by 156
Asaoka, D., Xiao, J., Takeda, T., Yanagisawa, N., Yamazaki, T., Matsubara, Y., Sugiyama, H., Endo, N., Higa, M., Kasanuki, K., et al. (2022) · Journal of Alzheimer's Disease · doi:10.3233/jad-220148 · Cited by 156
Faecal microbiota transplantation for Clostridioides difficile: mechanisms and pharmacology
Khoruts, A., Staley, C., & Sadowsky, M. J. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0350-4 · Cited by 155
Zheng, J., Li, H.-L., Tian, N., Liu, F., Wang, L., Yin, Y., Yue, L., Ma, L., Wan, Y., & Wang, J.-Z. (2020) · Cell Stem Cell · doi:10.1016/j.stem.2019.12.015 · Cited by 154
Jiang, Y., Li, K., Li, X., Xu, L., & Yang, Z. (2021) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2021.109452 · Cited by 154
Wang, R., Cao, S., Bashir, M. E. H., Hesser, L. A., Su, Y., Hong, S. M. C., Thompson, A., Culleen, E., Sabados, M., Dylla, N. P., et al. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00972-5 · Cited by 154
Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors
Simpson, R. C., Shanahan, E. R., Scolyer, R. A., & Long, G. V. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00803-9 · Cited by 153
Tu, H., Yuan, B., Hou, X., Zhang, X., Pei, C., Ma, Y., Yang, Y., Fan, Y., Qin, Z., Liu, C., et al. (2021) · Aging Cell · doi:10.1111/acel.13522 · Cited by 152
Simone, R. D., Vissicchio, F., Mingarelli, C., Nuccio, C. D., Visentin, S., Ajmone‐Cat, M. A., & Minghetti, L. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.02.001 · Cited by 151
A prospective longitudinal study on the microbiota composition in amyotrophic lateral sclerosis
Di Gioia, D., Bozzi Cionci, N., Baffoni, L., Amoruso, A., Pane, M., Mogna, L., Gaggìa, F., Lucenti, M. A., Bersano, E., Cantello, R., et al. (2020) · BMC Medicine · doi:10.1186/s12916-020-01607-9 · Cited by 151
Microglial amyloid beta clearance is driven by PIEZO1 channels
Jäntti, H., Sitnikova, V., Ishchenko, Y., Shakirzyanova, A., Giudice, L., Ugidos, I. F., Gómez-Budia, M., Korvenlaita, N., Ohtonen, S., Belaya, I., et al. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02486-y · Cited by 151
Sun, Y., Zhang, H., Zhang, X., Wang, W., Chen, Y., Cai, Z., Wang, Q., Wang, J., & Shi, Y. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102690 · Cited by 151
Timing and Impact of Psychiatric, Cognitive, and Motor Abnormalities in Huntington Disease
McAllister, B., Gusella, J. F., Landwehrmeyer, G. B., Lee, J., MacDonald, M. E., Orth, M., Rosser, A., Williams, N. M., Holmans, P., Jones, L., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000011893 · Cited by 150
Yan, Y., Yu, L., Qu, Y., Fan, Z., Zhang, T., Xu, Y., Du, Q., Brügger, D., Chen, Y., Zhang, K., et al. (2023) · npj Biofilms and Microbiomes · doi:10.1038/s41522-023-00420-5 · Cited by 149
Insights into Alzheimer’s disease from single-cell genomic approaches
Murdock, M. H., & Tsai, L.-H. (2023) · Nature Neuroscience · doi:10.1038/s41593-022-01222-2 · Cited by 148
Basal forebrain cholinergic signalling: development, connectivity and roles in cognition
Ananth, M. R., Rajebhosale, P., Kim, R., Talmage, D. A., & Role, L. W. (2023) · Nature Reviews Neuroscience · doi:10.1038/s41583-023-00677-x · Cited by 148
Gut Microbiota Dysbiosis Is Associated with Elevated Bile Acids in Parkinson’s Disease
Li, P., Killinger, B. A., Ensink, E., Beddows, I., Yilmaz, A., Lubben, N., Lamp, J., Schilthuis, M., Vega, I. E., Woltjer, R., et al. (2021) · Metabolites · doi:10.3390/metabo11010029 · Cited by 146
NAD precursors cycle between host tissues and the gut microbiome
Chellappa, K., McReynolds, M. R., Lu, W., Zeng, X., Makarov, M., Hayat, F., Mukherjee, S., Bhat, Y. R., Lingala, S. R., Shima, R. T., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.11.004 · Cited by 146
Methanogenic archaea in the human gastrointestinal tract
Högenauer, C., Hammer, H. F., Mahnert, A., & Moissl‐Eichinger, C. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00673-z · Cited by 146
Lai, Y., Liu, C.-W., Yang, Y., Hsiao, Y.-C., Ru, H., & Lu, K. (2021) · Nature Communications · doi:10.1038/s41467-021-26209-8 · Cited by 145
Tian, P., Zou, R., Wang, L., Chen, Y., Qian, X., Zhao, J., Zhang, H., Qian, L., Wang, Q., Wang, G., et al. (2022) · Journal of Advanced Research · doi:10.1016/j.jare.2022.05.003 · Cited by 145
Ghrelin antagonizes MPTP-induced neurotoxicity to the dopaminergic neurons in mouse substantia nigra
Jiang, H., Li, L.-J., Wang, J., & Xie, J.-X. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2008.05.006 · Cited by 144
The intestine as an endocrine organ and the role of gut hormones in metabolic regulation
Bany Bakar, R., Reimann, F., & Gribble, F. M. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00830-y · Cited by 144
Human metabolome variation along the upper intestinal tract
Folz, J., Culver, R. N., Morales, J. M., Grembi, J., Triadafilopoulos, G., Relman, D. A., Huang, K. C., Shalon, D., & Fiehn, O. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00777-z · Cited by 143
Horvath, T. D., Ihekweazu, F. D., Haidacher, S. J., Ruan, W., Engevik, K. A., Fultz, R., Hoch, K. M., Luna, R. A., Oezguen, N., Spinler, J. K., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104158 · Cited by 142
Zhang, Z.-W., Gao, C.-S., Zhang, H., Yang, J., Wang, Y.-P., Pan, L.-B., Yu, H., He, C.-Y., Luo, H.-B., Zhao, Z.-X., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.02.032 · Cited by 139
Characterization of interactions of dietary cholesterol with the murine and human gut microbiome
Le, H. H., Lee, M.-T., Besler, K. R., Comrie, J. M. C., & Johnson, E. L. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01195-9 · Cited by 139
Wong, C. K., Yusta, B., Koehler, J. A., Baggio, L. L., McLean, B. A., Matthews, D., Seeley, R. J., & Drucker, D. J. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.08.003 · Cited by 138
Humphrey, J., Venkatesh, S., Hasan, R., Herb, J. T., de Paiva Lopes, K., Küçükali, F., Byrska-Bishop, M., Evani, U. S., Narzisi, G., Fagegaltier, D., et al. (2023) · Nature Neuroscience · doi:10.1038/s41593-022-01205-3 · Cited by 138
Wang, Z.-H., Gong, K., Liu, X., Zhang, Z., Sun, X., Wei, Z. Z., Yu, S. P., Manfredsson, F. P., Sandoval, I. M., Johnson, P. F., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04120-z · Cited by 137
Myelin as a regulator of development of the microbiota-gut-brain axis
Keogh, C. E., Kim, D. H. J., Pusceddu, M. M., Knotts, T. A., Rabasa, G., Sladek, J. A., Hsieh, M. T., Honeycutt, M., Brust-Mascher, I., Barboza, M., et al. (2021) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.11.001 · Cited by 137
Li, J., Li, Y., Ivey, K. L., Wang, D. D., Wilkinson, J. E., Franke, A., Lee, K. H., Chan, A., Huttenhower, C., Hu, F. B., et al. (2022) · Gut · doi:10.1136/gutjnl-2020-322473 · Cited by 137
Probiotics synergized with conventional regimen in managing Parkinson’s disease
Sun, H., Zhao, F., Liu, Y., Ma, T., Jin, H., Quan, K., Leng, B., Zhao, J., Yuan, X., Li, Z., et al. (2022) · npj Parkinson's Disease · doi:10.1038/s41531-022-00327-6 · Cited by 136
Incretin and insulin signaling as novel therapeutic targets for Alzheimer’s and Parkinson’s disease
Nowell, J., Blunt, E., & Edison, P. (2023) · Molecular Psychiatry · doi:10.1038/s41380-022-01792-4 · Cited by 136
Brelstaff, J. H., Mason, M., Katsinelos, T., McEwan, W. A., Ghetti, B., Tolkovsky, A. M., & Spillantini, M. G. (2021) · Science Advances · doi:10.1126/sciadv.abg4980 · Cited by 135
Casado, M. E., Collado‐Perez, R., Frago, L. M., & Barrios, V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021422 · Cited by 135
Dietary ω-3 Polyunsaturated Fatty Acid Intake and Risk for Amyotrophic Lateral Sclerosis
Fitzgerald, K. C., O’Reilly, É. J., Falcone, G. J., McCullough, M. L., Park, Y., Kolonel, L. N., & Ascherio, A. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.1214 · Cited by 134
Alarcón-Arís, D., Recasens, A., Galofré, M., Carballo-Carbajal, I., Zacchi, N., Ruiz-Bronchal, E., Pavia-Collado, R., Chica, R., Ferrés-Coy, A., Santos, M., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.11.015 · Cited by 134
Mahan, T. E., Wang, C., Bao, X., Choudhury, A., Ulrich, J. D., & Holtzman, D. M. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00516-0 · Cited by 134
Teng, Y., Mu, J., Xu, F., Zhang, X., Sriwastva, M. K., Liu, Q. M., Li, X., Lei, C., Sundaram, K., Hu, X., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.05.005 · Cited by 134
Aljumaah, M. R., Bhatia, U., Roach, J., Gunstad, J., & Azcarate Peril, M. A. (2022) · Clinical Nutrition · doi:10.1016/j.clnu.2022.09.012 · Cited by 132
Fujii, Y., Nguyen, T. T. T., Fujimura, Y., Kameya, N., Nakamura, S., Arakawa, K., & Morita, H. (2019) · Bioscience, Biotechnology, and Biochemistry · doi:10.1080/09168451.2019.1644149 · Cited by 132
Lancaster, S. M., Lee‐McMullen, B., Abbott, C. W., Quijada, J. V., Hornburg, D., Park, H., Perelman, D., Peterson, D. J., Tang, M., Robinson, A., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.03.036 · Cited by 132
The Impact of Type 2 Diabetes in Parkinson's Disease
Athauda, D., Evans, J., Wernick, A., Virdi, G., Choi, M. L., Lawton, M., Vijiaratnam, N., Girges, C., Ben‐Shlomo, Y., Ismail, K., et al. (2022) · Movement Disorders · doi:10.1002/mds.29122 · Cited by 132
Neuronal APOE4 removal protects against tau-mediated gliosis, neurodegeneration and myelin deficits
Koutsodendris, N., Blumenfeld, J., Agrawal, A., Traglia, M., Grone, B., Zilberter, M., Yip, O., Rao, A., Nelson, M. R., Hao, Y., et al. (2023) · Nature Aging · doi:10.1038/s43587-023-00368-3 · Cited by 132
Bennett, S. A., Tanaz, R., Cobos, S. N., & Torrente, M. P. (2019) · Translational Research · doi:10.1016/j.trsl.2018.10.002 · Cited by 130
Microglial-to-neuronal CCR5 signaling regulates autophagy in neurodegeneration
Festa, B. P., Siddiqi, F. H., Jimenez-Sanchez, M., Won, H., Rob, M., Djajadikerta, A., Stamatakou, E., & Rubinsztein, D. C. (2023) · Neuron · doi:10.1016/j.neuron.2023.04.006 · Cited by 129
Lopetuso, L. R., Deleu, S., Godny, L., Petito, V., Puca, P., Facciotti, F., Sokol, H., Ianiro, G., Masucci, L., Abreu, M., et al. (2023) · Gut · doi:10.1136/gutjnl-2023-329948 · Cited by 129
Brown, G. C. (2024) · Nature Reviews Immunology · doi:10.1038/s41577-023-00921-6 · Cited by 129
Wang, Q.-J., Shen, Y.-E., Wang, X., Fu, S., Zhang, X., Zhang, Y.-N., & Wang, R.-T. (2020) · Aging · doi:10.18632/aging.102645 · Cited by 128
Abdelkader, N. F., Safar, M. M., & Salem, H. A. (2016) · Molecular Neurobiology · doi:10.1007/s12035-014-9043-8 · Cited by 127
Dionísio, P. A., Amaral, J. D., Ribeiro, M. F., Lo, A. C., D'Hooge, R., & Rodrigues, C. M. P. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.08.034 · Cited by 127
The alteration of gut microbiome and metabolism in amyotrophic lateral sclerosis patients
Zeng, Q., Shen, J., Chen, K., Zhou, J., Liao, Q., Lu, K., Yuan, J., & Bi, F. (2020) · Scientific Reports · doi:10.1038/s41598-020-69845-8 · Cited by 127
Lynch, C. M. K., Cowan, C. S. M., Bastiaanssen, T. F. S., Moloney, G. M., Theune, N., van de Wouw, M., Florensa Zanuy, E., Ventura-Silva, A. P., Codagnone, M. G., Villalobos-Manríquez, F., et al. (2023) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2022.12.008 · Cited by 127
Bhattarai, Y., Si, J., Pu, M., Ross, O. A., McLean, P. J., Till, L., Moor, W., Grover, M., Kandimalla, K. K., Margolis, K. G., et al. (2021) · Gut Microbes · doi:10.1080/19490976.2020.1866974 · Cited by 126
The gut microbiota promotes distal tissue regeneration via RORγ+ regulatory T cell emissaries
Hanna, B. S., Wang, G., Galván-Peña, S., Mann, A. O., Ramirez, R. N., Muñoz-Rojas, A. R., Smith, K., Wan, M., Benoist, C., & Mathis, D. (2023) · Immunity · doi:10.1016/j.immuni.2023.01.033 · Cited by 126
Regulatory T cells in the face of the intestinal microbiota
Ramanan, D., Pratama, A., Zhu, Y., Venezia, O., Sassone-Corsi, M., Chowdhary, K., Galván-Peña, S., Sefik, E., Brown, C., Gélineau, A., et al. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-023-00890-w · Cited by 126
Evaluation of Adiposity and Cognitive Function in Adults
Anand, S. S., Friedrich, M. G., Lee, D. S., Awadalla, P., Després, J. P., Desai, D., de Souza, R. J., Dummer, T., Parraga, G., Larose, E., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.46324 · Cited by 125
Neuroinflammation and protein aggregation co-localize across the frontotemporal dementia spectrum
Bevan-Jones, W. R., Cope, T. E., Jones, P. S., Kaalund, S. S., Passamonti, L., Allinson, K., Green, O., Hong, Y. T., Fryer, T. D., Arnold, R., et al. (2020) · Brain · doi:10.1093/brain/awaa033 · Cited by 124
on behalf of AddNeuroMed consortium, Whiley, L., Chappell, K. E., D’Hondt, E., Lewis, M. R., Jiménez, B., Snowden, S. G., Soininen, H., Kłoszewska, I., Mecocci, P., et al. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00741-z · Cited by 124
Fecal microbiota transplant as a potential treatment for Parkinson's disease – A case series
Segal, A., Zlotnik, Y., Moyal-Atias, K., Abuhasira, R., & Ifergane, G. (2021) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2021.106791 · Cited by 124
Hall, D. A., Voigt, R. M., Cantu-Jungles, T. M., Hamaker, B., Engen, P. A., Shaikh, M., Raeisi, S., Green, S. J., Naqib, A., Forsyth, C. B., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36497-x · Cited by 124
Defining blood-induced microglia functions in neurodegeneration through multiomic profiling
Mendiola, A. S., Yan, Z., Dixit, K., Johnson, J. R., Bouhaddou, M., Meyer-Franke, A., Shin, M.-G., Yong, Y., Agrawal, A., MacDonald, E., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01522-0 · Cited by 124
The human gut microbiota in people with amyotrophic lateral sclerosis
Nicholson, K., Bjornevik, K., Abu-Ali, G., Chan, J., Cortese, M., Dedi, B., Jeon, M., Xavier, R., Huttenhower, C., Ascherio, A., et al. (2021) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.1080/21678421.2020.1828475 · Cited by 123
Wile, D. J., Agarwal, P. A., Schulzer, M., Mak, E., Dinelle, K., Shahinfard, E., Vafai, N., Hasegawa, K., Zhang, J., McKenzie, J., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30056-x · Cited by 122
Astrocyte and neuron cooperation in long-term depression
Durkee, C. A., Kofuji, P., Navarrete, M., & Araque, A. (2021) · Trends in Neurosciences · doi:10.1016/j.tins.2021.07.004 · Cited by 121
Biointerface mineralization generates ultraresistant gut microbes as oral biotherapeutics
Geng, Z., Wang, X., Wu, F. Q., Cao, Z., & Liu, J. (2023) · Science Advances · doi:10.1126/sciadv.ade0997 · Cited by 121
Lo, A. C., Callaerts-Vegh, Z., Nunes, A. F., Rodrigues, C. M. P., & D'Hooge, R. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.09.003 · Cited by 120
Mezö, C., Dokalis, N., Mossad, O., Staszewski, O., Neuber, J., Yilmaz, B., Schnepf, D., de Agüero, M. G., Ganal-Vonarburg, S. C., Macpherson, A. J., et al. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-00988-5 · Cited by 120
Gut microbiota–driven brain Aβ amyloidosis in mice requires microglia
Dodiya, H. B., Lutz, H. L., Weigle, I. Q., Patel, P., Michalkiewicz, J., Roman-Santiago, C. J., Zhang, C. M., Liang, Y., Srinath, A., Zhang, X., et al. (2022) · Journal of Experimental Medicine · doi:10.1084/jem.20200895 · Cited by 120
The gut microbiota and depressive symptoms across ethnic groups
Bosch, J. A., Nieuwdorp, M., Zwinderman, A. H., Deschasaux, M., Radjabzadeh, D., Kraaij, R., Davids, M., de Rooij, S. R., & Lok, A. (2022) · Nature Communications · doi:10.1038/s41467-022-34504-1 · Cited by 120
Yin, Z., Herron, S., Silveira, S., Kleemann, K., Gauthier, C., Mallah, D., Cheng, Y., Margeta, M. A., Pitts, K. M., Barry, J.-L., et al. (2023) · Nature Neuroscience · doi:10.1038/s41593-023-01355-y · Cited by 120
Masse, K. E., & Lu, V. B. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1169624 · Cited by 120
Wang, R., Guo, K., zhang, W., He, Y., Yang, K., Chen, Q., Yang, L., Di, Z., Qiu, J., Lei, P., et al. (2022) · Advanced Functional Materials · doi:10.1002/adfm.202113034 · Cited by 119
Roles of the gut microbiome in weight management
Carmody, R. N., & Bisanz, J. E. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00888-0 · Cited by 118
Gao, Q., Wang, Y., Wang, X., Fu, S., Zhang, X., Wang, R.-T., & Zhang, X. (2019) · Aging · doi:10.18632/aging.102352 · Cited by 117
Huang, F., Pariante, C. M., & Borsini, A. (2022) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2021.09.021 · Cited by 117
Thinking outside the box: non-canonical targets in multiple sclerosis
Bierhansl, L., Hartung, H.-P., Aktas, O., Ruck, T., Roden, M., & Meuth, S. G. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00477-5 · Cited by 117
Li, N., Tan, S., Wang, Y., Deng, J., Wang, N., Zhu, S., Tian, W., Xu, J., & Wang, Q. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2252764 · Cited by 117
Nishiwaki, H., Ito, M., Hamaguchi, T., Maeda, T., Kashihara, K., Tsuboi, Y., Ueyama, J., Yoshida, T., Hanada, H., Takeuchi, I., et al. (2022) · npj Parkinson's Disease · doi:10.1038/s41531-022-00328-5 · Cited by 116
Quantifying bias introduced by sample collection in relative and absolute microbiome measurements
Maghini, D. G., Dvorak, M., Dahlen, A., Roos, M., Doyle, B., Kuersten, S., & Bhatt, A. S. (2024) · Nature Biotechnology · doi:10.1038/s41587-023-01754-3 · Cited by 116
Guo, Y., Zhu, X., Zeng, M., Qi, L., Tang, X., Wang, D., Zhang, M., Xie, Y., Li, H., Yang, X., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01443-2 · Cited by 116
Fujitsuka, N., Asakawa, A., Morinaga, A., Amitani, M. S., Amitani, H., Katsuura, G., Sawada, Y., Sudo, Y., Uezono, Y., Mochiki, E., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.220 · Cited by 114
Heiss, C. N., Mannerås-Holm, L., Lee, Y. S., Serrano-Lobo, J., Håkansson Gladh, A., Seeley, R. J., Drucker, D. J., Bäckhed, F., & Olofsson, L. E. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109163 · Cited by 114
Gut Metabolite TMAO Induces Synaptic Plasticity Deficits by Promoting Endoplasmic Reticulum Stress
Govindarajulu, M., Pinky, P. D., Steinke, I., Bloemer, J., Ramesh, S., Kariharan, T., Rella, R. T., Bhattacharya, S., Dhanasekaran, M., Suppiramaniam, V., et al. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00138 · Cited by 113
Pan, W., Zhao, J., Wu, J., Xu, D., Meng, X., Jiang, P., Shi, H., Ge, X., Yang, X., Hu, M., et al. (2023) · Microbiome · doi:10.1186/s40168-023-01471-8 · Cited by 113
Nrf2 activation by tauroursodeoxycholic acid in experimental models of Parkinson's disease
Moreira, S., Fonseca, I., Nunes, M. J., Rosa, A., Lemos, L., Rodrigues, E., Carvalho, A. N., Outeiro, T. F., Rodrigues, C. M. P., Gama, M. J., et al. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.05.009 · Cited by 112
The contribution of glial cells to Huntington's disease pathogenesis
Wilton, D. K., & Stevens, B. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104963 · Cited by 112
The gut microbiome modulates the transformation of microglial subtypes
Huang, Y., Wu, J., Zhang, H., Li, Y., Wen, L., Tan, X., Cheng, K., Liu, Y., Pu, J., Liu, L., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02017-y · Cited by 111
Fu, J., Li, J., Sun, Y., Liu, S., Song, F., & Liu, Z. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.123488 · Cited by 111
Beneficial effects of butyrate on brain functions: A view of epigenetic
Alpino, G. D. C. Á., Pereira-Sol, G. A., Dias, M. D. M. E., Aguiar, A. S. D., & Peluzio, M. D. C. G. (2024) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2022.2137776 · Cited by 110
Pomilio, C., Gorojod, R. M., Riudavets, M., Vinuesa, A., Presa, J., Gregosa, A., Bentivegna, M., Alaimo, A., Alcon, S. P., Sevlever, G., et al. (2020) · GeroScience · doi:10.1007/s11357-020-00161-9 · Cited by 109
Rhee, S. Y., Han, K.-D., Kwon, H., Park, S.-E., Park, Y.-G., Kim, Y.-H., Yoo, S.-J., Rhee, E.-J., & Lee, W.-Y. (2020) · Diabetes Care · doi:10.2337/dc19-0760 · Cited by 109
A cell therapy approach to restore microglial Trem2 function in a mouse model of Alzheimer’s disease
Yoo, Y., Neumayer, G., Shibuya, Y., Mader, M. M.-D., & Wernig, M. (2023) · Cell Stem Cell · doi:10.1016/j.stem.2023.07.006 · Cited by 109
Fazal, R., Boeynaems, S., Swijsen, A., De Decker, M., Fumagalli, L., Moisse, M., Vanneste, J., Guo, W., Boon, R., Vercruysse, T., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2020106177 · Cited by 108
Adaptive and maladaptive myelination in health and disease
Knowles, J. K., Batra, A., Xu, H., & Monje, M. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00737-3 · Cited by 108
Xia, Y., Xiao, Y., Wang, Z.-H., Liu, X., Alam, A. M., Haran, J. P., McCormick, B. A., Shu, X., Wang, X., & Ye, K. (2023) · Nature Communications · doi:10.1038/s41467-023-41283-w · Cited by 108
Augusto‐Oliveira, M., Arrifano, G. P., Delage, C. I., Tremblay, M., Crespo‐Lopez, M. E., & Verkhratsky, A. (2022) · Biological Reviews · doi:10.1111/brv.12797 · Cited by 107
Pan, R.-Y., Zhang, J., Wang, J., Wang, Y., Li, Z., Liao, Y., Liao, Y., Zhang, C., Liu, Z., Song, L., et al. (2022) · Nature Aging · doi:10.1038/s43587-022-00311-y · Cited by 107
Microglia control glutamatergic synapses in the adult mouse hippocampus
Basilico, B., Ferrucci, L., Ratano, P., Golia, M. T., Grimaldi, A., Rosito, M., Ferretti, V., Reverte, I., Sanchini, C., Marrone, M. C., et al. (2022) · Glia · doi:10.1002/glia.24101 · Cited by 107
A biosynthetic pathway for the selective sulfonation of steroidal metabolites by human gut bacteria
Yao, L., D’Agostino, G. D., Park, J., Hang, S., Adhikari, A. A., Zhang, Y., Li, W., Ávila-Pacheco, J., Bae, S., Clish, C. B., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01176-y · Cited by 106
Sankowski, B., Księżarczyk, K., Raćkowska, E., Szlufik, S., Koziorowski, D., & Giebułtowicz, J. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2019.10.038 · Cited by 105
Zhao, N., Chen, Q.-G., Chen, X., Liu, X.-T., Geng, F., Zhu, M.-M., Yan, F.-L., Zhang, Z.-J., & Ren, Q.-G. (2023) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2022.11.013 · Cited by 105
Myelination-independent functions of oligodendrocyte precursor cells in health and disease
Xiao, Y. C., & Czopka, T. (2023) · Nature Neuroscience · doi:10.1038/s41593-023-01423-3 · Cited by 105
Peptide hormone ghrelin enhances neuronal excitability by inhibition of Kv7/KCNQ channels
Shi, L., Bian, X., Qu, Z., Ma, Z., Zhou, Y., Wang, K., Jiang, H., & Xie, J. (2013) · Nature Communications · doi:10.1038/ncomms2439 · Cited by 103
Roberts, K., Zeineddine, R., Corcoran, L., Li, W., Campbell, I. L., & Yerbury, J. J. (2013) · Glia · doi:10.1002/glia.22444 · Cited by 103
Yanguas-Casás, N., Barreda-Manso, M. A., Nieto-Sampedro, M., & Romero-Ramírez, L. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-50 · Cited by 103
Nuzum, N. D., Loughman, A., Szymlek-Gay, E. A., Hendy, A., Teo, W.-P., & Macpherson, H. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.02.003 · Cited by 103
Wilson, H., Dervenoulas, G., Pagano, G., Koros, C., Yousaf, T., Picillo, M., Polychronis, S., Simitsi, A., Giordano, B., Chappell, Z., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30140-1 · Cited by 102
Genome–microbiome interplay provides insight into the determinants of the human blood metabolome
Diener, C., Dai, C. L., Wilmanski, T., Baloni, P., Smith, B., Rappaport, N., Hood, L., Magis, A. T., & Gibbons, S. M. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00670-1 · Cited by 102
Borzabadi, S., Oryan, S., Eidi, A., Aghadavod, E., Kakhaki, R. D., Tamtaji, O. R., Taghizadeh, M., & Asemi, Z. (2018) · PubMed · Cited by 101
Increased intestinal permeability and gut dysbiosis in the R6/2 mouse model of Huntington’s disease
Stan, T. L., Soylu-Kucharz, R., Burleigh, S., Prykhodko, O., Cao, L., Franke, N., Sjögren, M., Haikal, C., Hållenius, F., & Björkqvist, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-75229-9 · Cited by 101
Neuroprotective effects of short-chain fatty acids in MPTP induced mice model of Parkinson's disease
Hou, Y., Li, X., Liu, C., Zhang, M., Zhang, X., Ge, S., & Zhao, L. (2021) · Experimental Gerontology · doi:10.1016/j.exger.2021.111376 · Cited by 101
Han, D., Li, Z., Liu, T., Yang, N., Li, Y., He, J., Qian, M., Kuang, Z., Zhang, W., Ni, C., et al. (2020) · Aging and disease · doi:10.14336/ad.2020.0106 · Cited by 99
Shiga Toxin–Producing Escherichia coli Transmission via Fecal Microbiota Transplant
Zellmer, C., Sater, M. R. A., Huntley, M. H., Osman, M., Olesen, S. W., & Ramakrishna, B. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1486 · Cited by 98
The microbiota–microglia axis in central nervous system disorders
Mossad, O., & Erny, D. (2020) · Brain Pathology · doi:10.1111/bpa.12908 · Cited by 98
Brydges, C. R., Fiehn, O., Mayberg, H. S., Schreiber, H., Dehkordi, S. M., Bhattacharyya, S., Cha, J., Choi, K. S., Craighead, W. E., Krishnan, R. R., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-99845-1 · Cited by 98
Luo, S., Zhang, X., Huang, S. Q., Feng, X., Zhang, X., & Xiang, D.-X. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.05.185 · Cited by 98
Matsudaira, T., Nakano, S., Konishi, Y., Kawamoto, S., Uemura, K., Kondo, T., Sakurai, K., Ozawa, T., Hikida, T., Komine, O., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-05027-2 · Cited by 98
The GABAergic system in Alzheimer’s disease: a systematic review with meta-analysis
Carello-Collar, G., Bellaver, B., Ferreira, P. C. L., Ferrari-Souza, J. P., Ramos, V. G., Therriault, J., Tissot, C., De Bastiani, M. A., Soares, C., Pascoal, T. A., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02140-w · Cited by 98
Unger, M. M., Möller, J. C., Mankel, K., Eggert, K. M., Bohne, K., Bodden, M., Stiasny-Kolster, K., Kann, P. H., Mayer, G., Tebbe, J. J., et al. (2011) · Journal of Neurology · doi:10.1007/s00415-010-5864-1 · Cited by 97
Varma, V. R., Wang, Y., An, Y., Varma, S., Bilgel, M., Doshi, J., Legido-Quigley, C., Delgado, J. C., Oommen, A. M., Roberts, J. A., et al. (2021) · PLOS Medicine · doi:10.1371/journal.pmed.1003615 · Cited by 97
Knox, E. G., Aburto, M. R., Tessier, C., Nagpal, J., Clarke, G., O’Driscoll, C. M., & Cryan, J. F. (2022) · iScience · doi:10.1016/j.isci.2022.105648 · Cited by 97
Yan, Z., Yang, F., Sun, L., Yu, J., Sun, L., Si, Y., & Yao, L. (2022) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2022.09.009 · Cited by 95
Tauroursodeoxycholic acid improves motor symptoms in a mouse model of Parkinson's disease
Rosa, A. I., Duarte-Silva, S., Silva-Fernandes, A., Nunes, M. J., Carvalho, A. N., Rodrigues, E., Gama, M. J., Rodrigues, C. M. P., Maciel, P., & Castro-Caldas, M. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1062-4 · Cited by 94
Figueroa-Romero, C., Guo, K., Murdock, B. J., Paez-Colasante, X., Bassis, C. M., Mikhail, K. A., Raue, K. D., Evans, M. C., Taubman, G. F., McDermott, A. J., et al. (2019) · Disease Models & Mechanisms · doi:10.1242/dmm.041947 · Cited by 94
Pan, H., Sun, T., Cui, M., Ma, N., Yang, C., Liu, J., Pang, G., Liu, B., Li, L., Zhang, X., et al. (2022) · ACS Nano · doi:10.1021/acsnano.1c11536 · Cited by 94
Rossaert, E., Pollari, E., Jaspers, T., Van Helleputte, L., Jarpe, M., Van Damme, P., De Bock, K., Moisse, M., & Van Den Bosch, L. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0750-2 · Cited by 93
Association of a common genetic variant with Parkinson’s disease is mediated by microglia
Langston, R. G., Beilina, A., Reed, X., Kaganovich, A., Singleton, A. B., Blauwendraat, C., Gibbs, J. R., & Cookson, M. R. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abp8869 · Cited by 93
ALS motor neurons exhibit hallmark metabolic defects that are rescued by SIRT3 activation
Hor, J., Santosa, M. M., Lim, V. J. W., Ho, B. X., Taylor, A., Khong, Z. J., Ravits, J., Fan, Y., Liou, Y., Soh, B.-S., et al. (2020) · Cell Death and Differentiation · doi:10.1038/s41418-020-00664-0 · Cited by 92
Diet leaves a genetic signature in a keystone member of the gut microbiota
Dapa, T., Ramiro, R. S., Pedro, M. F., Gordo, I., & Xavier, K. B. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.01.002 · Cited by 91
Zhang, Y., He, X., Qian, Y., Xu, S., Mo, C., Yan, Z., Yang, X., & Xiao, Q. (2022) · npj Parkinson s Disease · doi:10.1038/s41531-022-00312-z · Cited by 91
Song, L., Sun, Q., Zheng, H., Zhang, Y., Wang, Y., Liu, S., & Duan, L. (2022) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202200164 · Cited by 91
Zhang, Y., Bailey, J. T., Xu, E., Singh, K., Lavaert, M., Link, V. M., D’Souza, S., Hafiz, A., Cao, J., Cao, G., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01349-1 · Cited by 91
Microglia modulate hippocampal synaptic transmission and sleep duration along the light/dark cycle
Corsi, G., Picard, K., di Castro, M. A., Garofalo, S., Tucci, F., Chece, G., del Percio, C., Golia, M. T., Raspa, M., Scavizzi, F., et al. (2022) · Glia · doi:10.1002/glia.24090 · Cited by 90
Wang, D., Doestzada, M., Chen, L., Andreu-Sánchez, S., van den Munckhof, I. C. L., Augustijn, H. E., Koehorst, M., Ruiz-Moreno, A. J., Bloks, V. W., Riksen, N. P., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.11.003 · Cited by 90
Alterations of gut microbiota and metabolome with Parkinson's disease
Yan, Z., Yang, F., Cao, J., Ding, W., Yan, S., Shi, W., Wen, S., & Yao, L. (2021) · Microbial Pathogenesis · doi:10.1016/j.micpath.2021.105187 · Cited by 89
Endothelial sensing of AHR ligands regulates intestinal homeostasis
Wiggins, B. G., Wang, Y.-F., Burke, A., Grunberg, N., Vlachaki Walker, J. M., Dore, M., Chahrour, C., Pennycook, B. R., Sanchez-Garrido, J., Vernia, S., et al. (2023) · Nature · doi:10.1038/s41586-023-06508-4 · Cited by 89
Singh, A., Zapata, R. C., Pezeshki, A., Reidelberger, R. D., & Chelikani, P. K. (2018) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2018.05.017 · Cited by 87
Svahn, A. J., Don, E. K., Badrock, A. P., Cole, N. J., Graeber, M. B., Yerbury, J. J., Chung, R., & Morsch, M. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1875-2 · Cited by 87
The contribution of the peripheral immune system to neurodegeneration
Berriat, F., Lobsiger, C. S., & Boillée, S. (2023) · Nature Neuroscience · doi:10.1038/s41593-023-01323-6 · Cited by 87
Motor cortex transcriptome reveals microglial key events in amyotrophic lateral sclerosis
Dols-Icardo, O., Montal, V., Sirisi, S., López-Pernas, G., Cervera-Carles, L., Querol-Vilaseca, M., Muñoz, L., Belbin, O., Alcolea, D., Molina-Porcel, L., et al. (2020) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000829 · Cited by 86
Striatal glutamatergic hyperactivity in Parkinson's disease
Campanelli, F., Natale, G., Marino, G., Ghiglieri, V., & Calabresi, P. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105697 · Cited by 86
Akhgarjand, C., Vahabi, Z., Shab-Bidar, S., Etesam, F., & Djafarian, K. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1032494 · Cited by 85
Zhu, G., Zhao, J., Wang, G., & Chen, W. (2023) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.3c00652 · Cited by 84
Yang, X., He, X., Xu, S., Zhang, Y., Mo, C., Lai, Y., Song, Y., Zheng, Y., Ai, P., Qian, Y., et al. (2023) · Food & Function · doi:10.1039/d3fo00728f · Cited by 84
Sims, M. D., Khanna, S., Feuerstadt, P., Louie, T. J., Kelly, C. R., Huang, E. S., Hohmann, E. L., Wang, E. E. L., Oneto, C., Cohen, S. H., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.55758 · Cited by 83
The human gut microbiome of athletes: metagenomic and metabolic insights
Fontana, F., Longhi, G., Tarracchini, C., Mancabelli, L., Lugli, G. A., Alessandri, G., Turroni, F., Milani, C., & Ventura, M. (2023) · Microbiome · doi:10.1186/s40168-023-01470-9 · Cited by 83
Untargeted metabolomics yields insight into ALS disease mechanisms
Goutman, S. A., Boss, J., Guo, K., Alakwaa, F. M., Patterson, A., Kim, S., Savelieff, M. G., Hur, J., & Feldman, E. L. (2020) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2020-323611 · Cited by 83
Guo, T.-T., Zhang, Z., Sun, Y., Zhu, R.-Y., Wang, F.-X., Ma, L.-J., Jiang, L., & Liu, H.-D. (2023) · Nutrients · doi:10.3390/nu15040930 · Cited by 82
Tau at the interface between neurodegeneration and neuroinflammation
Didonna, A. (2020) · Genes & Immunity · doi:10.1038/s41435-020-00113-5 · Cited by 82
Parkinson's Disease Is Associated with Impaired Gut–Blood Barrier for Short‐Chain Fatty Acids
Yang, X., Ai, P., He, X., Mo, C., Zhang, Y., Xu, S., Lai, Y., Qian, Y., & Xiao, Q. (2022) · Movement Disorders · doi:10.1002/mds.29063 · Cited by 82
A prebiotic diet modulates microglial states and motor deficits in α-synuclein overexpressing mice
Abdel-Haq, R., Schlachetzki, J. C., Boktor, J. C., Cantu-Jungles, T. M., Thron, T., Zhang, M., Bostick, J. W., Khazaei, T., Chilakala, S., Morais, L. H., et al. (2022) · eLife · doi:10.7554/elife.81453 · Cited by 82
Serotonergic and Dopaminergic Lesions Underlying Parkinsonian Neuropsychiatric Signs
Maillet, A., Météreau, É., Tremblay, L., Favre, É., Klinger, H., Lhommée, E., Bars, D. L., Castrioto, A., Prange, S., Sgambato, V., et al. (2021) · Movement Disorders · doi:10.1002/mds.28722 · Cited by 82
Wang, N., Wang, M., Jeevaratnam, S., Rosenberg, C., Ikezu, T. C., Shue, F., Doss, S. V., Alnobani, A., Martens, Y. A., Wren, M., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00577-1 · Cited by 82
Gu, X., Zhou, J., Zhou, Y., Wang, H., Si, N., Ren, W., Zhao, W., Fan, X., Gao, W., Wei, X., et al. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00779-7 · Cited by 81
Cited by
Gut Microbiota Dysbiosis: Pathogenesis, Diseases, Prevention, and Therapy
Shen, Y., Fan, N., Ma, S., Cheng, X., Yang, X., & Wang, G. (2025) · MedComm · doi:10.1002/mco2.70168 · Cited by 301
Antibiotics and the gut microbiome: Understanding the impact on human health
Lathakumari, R. H., Vajravelu, L. K., Satheesan, A., Ravi, S., & Thulukanam, J. (2024) · Medicine in Microecology · doi:10.1016/j.medmic.2024.100106 · Cited by 147
Neuro-immune crosstalk in cancer: mechanisms and therapeutic implications
Pu, T., Sun, J., Ren, G., & Li, H. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02241-8 · Cited by 172
The Microbiota–Gut–Brain Axis and Neurological Disorders: A Comprehensive Review
Nakhal, M. M., Yassin, L. K., Alyaqoubi, R., Saeed, S., Alderei, A., Alhammadi, A., Alshehhi, M., Almehairbi, A., Houqani, S. A., BaniYas, S., et al. (2024) · Life · doi:10.3390/life14101234 · Cited by 154
Chen, C., Wang, G., Li, D., & Zhang, F. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00307-1 · Cited by 148
Metadata
- Authors
- Loh, J. S., Mak, W. Q., Tan, L. K. S., Ng, C. X., Chan, H. H., Yeow, S. H., Foo, J. B., Ong, Y. S., How, C. W., & Khaw, K. Y.
- Affiliations
- Monash University Malaysia (MY)
- Taylor's University (MY)
- UCL School of Pharmacy (GB)
- Corresponding author
- How, Chee Wun
- Khaw, Kooi Yeong
- ORCID
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2024-02-16
- Volume
- 9
- Issue
- 1
- Pages
- 37-37
- ISSN
- 2059-3635 (ISSN-L)
- PMC
- PMC10869798
- OpenAlex
- W4392783067
- Semantic Scholar
- c0e02114aa9a2a998ea241db2e5f6de2751e910e
- Cited by
- 1,193
- References
- 790
- Citations by year
- 2026: 551 · 2025: 509 · 2024: 131
- FWCI
- 48.46
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Greater South Information System
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- microbiota-gut-brain axis, gut microbiota, neurodegenerative diseases, glial cells, microglia, astrocytes, oligodendrocytes, gut microbiota metabolites, neurotransmitters, gastrointestinal hormones, intestinal barrier, blood-brain barrier, meninges, peripheral immune system, probiotics, prebiotics, fecal microbiota transplantation
- MeSH terms
- Brain-Gut Axis, Brain, Humans, Neurodegenerative Diseases, Probiotics, Prebiotics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.